Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 836
Filtrar
1.
BMJ Open ; 13(12): e073390, 2023 12 14.
Artículo en Inglés | MEDLINE | ID: mdl-38101834

RESUMEN

OBJECTIVE: The Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) partnered with the Ethiopian Pharmaceutical Supply Agency (EPSA) in 2018-2019 to reform procurement and supply chain management (PSCM) procedures within the Ethiopian healthcare system. This assessment sought to determine the impact of the reforms and document the lessons learnt. DESIGN: Mixed-methods study incorporating qualitative and quantitative analysis. Purposive and snowballing sampling techniques were applied for the qualitative methods, and the data collected was transcribed in full and subjected to thematic content analysis. Descriptive analysis was applied to quantitative data. SETTING: The study was based in Ethiopia and focused on the EPSA operations nationally between 2017 and 2021. PARTICIPANTS: Twenty-five Ethiopian healthcare decision-makers and health workers. INTERVENTION: Global Fund training programme for health workers and infrastructural improvements OUTCOMES: Operational and financial measures for healthcare PSCM. RESULTS: The availability of antiretrovirals, tuberculosis and malaria medicines, and other related commodities, remained consistently high. Line fill rate and forecast accuracy were average. Between 2018 and 2021, procurement lead times for HIV and malaria-related orders reduced by 43.0% relative to other commodities that reported an increase. Many interview respondents recognised the important role of the Global Fund support in improving the performance of EPSA and provided specific attributions to the observed successes. However, they were also clear that more needs to be done in specific critical areas such as financing, strategic reorganisation, data and information management systems. CONCLUSION: The Global Fund-supported initiatives led to improvements in the EPSA performance, despite several persistent challenges. To sustain and secure the gains achieved so far through Global Fund support and make progress, it is important that various stakeholders, including the government and the donor community, work together to support EPSA in delivering on its core mandate within the Ethiopian health system.


Asunto(s)
Síndrome de Inmunodeficiencia Adquirida , Salud Global , Malaria , Preparaciones Farmacéuticas , Tuberculosis , Humanos , Administración Financiera , Salud Global/economía , Cooperación Internacional , Malaria/tratamiento farmacológico , Malaria/economía , Malaria/prevención & control , Preparaciones Farmacéuticas/economía , Preparaciones Farmacéuticas/provisión & distribución , Tuberculosis/tratamiento farmacológico , Tuberculosis/economía , Tuberculosis/prevención & control , Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Síndrome de Inmunodeficiencia Adquirida/economía , Síndrome de Inmunodeficiencia Adquirida/prevención & control , Etiopía
2.
J Glob Health ; 13: 01005, 2023 Dec 20.
Artículo en Inglés | MEDLINE | ID: mdl-38115721
3.
JAMA ; 330(18): 1727-1728, 2023 11 14.
Artículo en Inglés | MEDLINE | ID: mdl-37707821

RESUMEN

This Viewpoint discusses the importance of the US Congress reauthorizing funding for the President's Emergency Plan for AIDS Relief, a program developed in 2003 that has played a critical role in fighting HIV/AIDS worldwide as well as other emerging infections and noncommunicable diseases.


Asunto(s)
Gobierno Federal , Financiación Gubernamental , Salud Global , Infecciones por VIH , Humanos , Salud Global/economía , Salud Global/legislación & jurisprudencia , Infecciones por VIH/economía , Infecciones por VIH/terapia , Cooperación Internacional/legislación & jurisprudencia , Estados Unidos , Financiación Gubernamental/legislación & jurisprudencia
4.
PLoS Negl Trop Dis ; 17(4): e0011204, 2023 04.
Artículo en Inglés | MEDLINE | ID: mdl-37079553

RESUMEN

The global 2030 goal set by the World Organization for Animal Health (WOAH), the World Health Organization (WHO), and the Food and Agriculture Organization (FAO), to eliminate dog-mediated human rabies deaths, has undeniably been a catalyst for many countries to re-assess existing dog rabies control programmes. Additionally, the 2030 agenda for Sustainable Development includes a blueprint for global targets which will benefit both people and secure the health of the planet. Rabies is acknowledged as a disease of poverty, but the connections between economic development and rabies control and elimination are poorly quantified yet, critical evidence for planning and prioritisation. We have developed multiple generalised linear models, to model the relationship between health care access, poverty, and death rate as a result of rabies, with separate indicators that can be used at country-level; total Gross Domestic Product (GDP), and current health expenditure as a percentage of the total gross domestic product (% GDP) as an indicator of economic growth; and a metric of poverty assessing the extent and intensity of deprivation experienced at the individual level (Multidimensional Poverty Index, MPI). Notably there was no detectable relationship between GDP or current health expenditure (% GDP) and death rate from rabies. However, MPI showed statistically significant relationships with per capita rabies deaths and the probability of receiving lifesaving post exposure prophylaxis. We highlight that those most at risk of not being treated, and dying due to rabies, live in communities experiencing health care inequalities, readily measured through poverty indicators. These data demonstrate that economic growth alone, may not be enough to meet the 2030 goal. Indeed, other strategies such as targeting vulnerable populations and responsible pet ownership are also needed in addition to economic investment.


Asunto(s)
Enfermedades de los Perros , Salud Global , Accesibilidad a los Servicios de Salud , Rabia , Animales , Perros , Humanos , Enfermedades de los Perros/economía , Enfermedades de los Perros/epidemiología , Enfermedades de los Perros/prevención & control , Salud Global/economía , Salud Global/estadística & datos numéricos , Pobreza/economía , Pobreza/estadística & datos numéricos , Rabia/economía , Rabia/epidemiología , Rabia/prevención & control , Rabia/veterinaria , Virus de la Rabia , Mortalidad , Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Desarrollo Económico/estadística & datos numéricos , Producto Interno Bruto/estadística & datos numéricos , Gastos en Salud/estadística & datos numéricos , Profilaxis Posexposición/economía , Profilaxis Posexposición/estadística & datos numéricos , Organización Mundial de la Salud
5.
JAMA ; 329(17): 1447-1448, 2023 05 02.
Artículo en Inglés | MEDLINE | ID: mdl-36995694

RESUMEN

This Viewpoint recommends increasing US global health funding levels, outlines steps for ensuring optimal integration and coordination of activities, and discusses ways to elevate noncommunicable diseases.


Asunto(s)
Salud Global , Financiación de la Atención de la Salud , Cooperación Internacional , Salud Global/economía , Estados Unidos
7.
JAMA ; 328(18): 1807-1808, 2022 11 08.
Artículo en Inglés | MEDLINE | ID: mdl-36279114

RESUMEN

This Viewpoint proposes restructuring the WHO Essential Medicines List to remove consideration of cost and cost-effectiveness from the expert committee reviews of clinical effectiveness, safety, and public health value, and chartering a new framework for pooled global negotiation and procurement of costly medicines included in the list.


Asunto(s)
Medicamentos Esenciales , Salud Global , Reforma de la Atención de Salud , Organización Mundial de la Salud , Medicamentos Esenciales/economía , Medicamentos Esenciales/normas , Salud Global/economía , Salud Global/normas , Reforma de la Atención de Salud/economía , Reforma de la Atención de Salud/normas
10.
Sci Rep ; 12(1): 666, 2022 01 13.
Artículo en Inglés | MEDLINE | ID: mdl-35027646

RESUMEN

The worldwide spread of the COVID-19 pandemic is a complex and multivariate process differentiated across countries, and geographical distance is acceptable as a critical determinant of the uneven spreading. Although social connectivity is a defining condition for virus transmission, the network paradigm in the study of the COVID-19 spatio-temporal spread has not been used accordingly. Toward contributing to this demand, this paper uses network analysis to develop a multidimensional methodological framework for understanding the uneven (cross-country) spread of COVID-19 in the context of the globally interconnected economy. The globally interconnected system of tourism mobility is modeled as a complex network and studied within the context of a three-dimensional (3D) conceptual model composed of network connectivity, economic openness, and spatial impedance variables. The analysis reveals two main stages in the temporal spread of COVID-19, defined by the cutting-point of the 44th day from Wuhan. The first describes the outbreak in Asia and North America, the second stage in Europe, South America, and Africa, while the outbreak in Oceania intermediates. The analysis also illustrates that the average node degree exponentially decays as a function of COVID-19 emergence time. This finding implies that the highly connected nodes, in the Global Tourism Network (GTN), are disproportionally earlier infected by the pandemic than the other nodes. Moreover, countries with the same network centrality as China are early infected on average by COVID-19. The paper also finds that network interconnectedness, economic openness, and transport integration are critical determinants in the early global spread of the pandemic, and it reveals that the spatio-temporal patterns of the worldwide spreading of COVID-19 are more a matter of network interconnectivity than of spatial proximity.


Asunto(s)
COVID-19/economía , COVID-19/transmisión , Salud Global/economía , Pandemias/economía , Brotes de Enfermedades/economía , Humanos , SARS-CoV-2/patogenicidad , Análisis Espacio-Temporal
11.
Eur Rev Med Pharmacol Sci ; 25(22): 7162-7184, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-34859882

RESUMEN

The last two decades have witnessed the emergence of three deadly coronaviruses (CoVs) in humans: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are still no reliable and efficient therapeutics to manage the devastating consequences of these CoVs. Of these, SARS-CoV-2, the cause of the currently ongoing coronavirus disease 2019 (COVID-19) pandemic, has posed great global health concerns. The COVID-19 pandemic has resulted in an unprecedented crisis with devastating socio-economic and health impacts worldwide. This highlights the fact that CoVs continue to evolve and have the genetic flexibility to become highly pathogenic in humans and other mammals. SARS-CoV-2 carries a high genetic homology to the previously identified CoV (SARS-CoV), and the immunological and pathogenic characteristics of SARS-CoV-2, SARS-CoV, and MERS contain key similarities and differences that can guide therapy and management. This review presents salient and updated information on comparative pathology, molecular pathogenicity, immunological features, and genetic characterization of SARS-CoV, MERS-CoV, and SARS-CoV-2; this can help in the design of more effective vaccines and therapeutics for countering these pathogenic CoVs.


Asunto(s)
COVID-19/virología , Coronavirus del Síndrome Respiratorio de Oriente Medio/genética , Patología Molecular/métodos , SARS-CoV-2/genética , Coronavirus Relacionado al Síndrome Respiratorio Agudo Severo/genética , Animales , COVID-19/diagnóstico , COVID-19/epidemiología , COVID-19/transmisión , Femenino , Salud Global/economía , Humanos , Masculino , Mamíferos , Coronavirus del Síndrome Respiratorio de Oriente Medio/inmunología , Coronavirus del Síndrome Respiratorio de Oriente Medio/patogenicidad , Coronavirus Relacionado al Síndrome Respiratorio Agudo Severo/inmunología , Coronavirus Relacionado al Síndrome Respiratorio Agudo Severo/patogenicidad , SARS-CoV-2/inmunología , SARS-CoV-2/patogenicidad , Virulencia
14.
Nat Med ; 27(10): 1761-1782, 2021 10.
Artículo en Inglés | MEDLINE | ID: mdl-34642490

RESUMEN

Anemia is a globally widespread condition in women and is associated with reduced economic productivity and increased mortality worldwide. Here we map annual 2000-2018 geospatial estimates of anemia prevalence in women of reproductive age (15-49 years) across 82 low- and middle-income countries (LMICs), stratify anemia by severity and aggregate results to policy-relevant administrative and national levels. Additionally, we provide subnational disparity analyses to provide a comprehensive overview of anemia prevalence inequalities within these countries and predict progress toward the World Health Organization's Global Nutrition Target (WHO GNT) to reduce anemia by half by 2030. Our results demonstrate widespread moderate improvements in overall anemia prevalence but identify only three LMICs with a high probability of achieving the WHO GNT by 2030 at a national scale, and no LMIC is expected to achieve the target in all their subnational administrative units. Our maps show where large within-country disparities occur, as well as areas likely to fall short of the WHO GNT, offering precision public health tools so that adequate resource allocation and subsequent interventions can be targeted to the most vulnerable populations.


Asunto(s)
Anemia/epidemiología , Estado Nutricional , Pobreza/economía , Adolescente , Adulto , Anemia/economía , Anemia/etiología , Anemia/patología , Países en Desarrollo/economía , Femenino , Salud Global/economía , Humanos , Persona de Mediana Edad , Prevalencia , Adulto Joven
17.
PLoS Med ; 18(9): e1003795, 2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-34534215

RESUMEN

BACKGROUND: The recent Lancet Commission on Legal Determinants of Global Health argues that governance can provide the framework for achieving sustainable development goals. Even though over 90% of fatal road traffic injuries occur in low- and middle-income countries (LMICs) primarily affecting motorcyclists, the utility of helmet laws outside of high-income settings has not been well characterized. We sought to evaluate the differences in outcomes of mandatory motorcycle helmet legislation and determine whether these varied across country income levels. METHODS AND FINDINGS: A systematic review and meta-analysis were completed using the PRISMA checklist. A search for relevant articles was conducted using the PubMed, Embase, and Web of Science databases from January 1, 1990 to August 8, 2021. Studies were included if they evaluated helmet usage, mortality from motorcycle crash, or traumatic brain injury (TBI) incidence, with and without enactment of a mandatory helmet law as the intervention. The Newcastle-Ottawa Scale (NOS) was used to rate study quality and funnel plots, and Begg's and Egger's tests were used to assess for small study bias. Pooled odds ratios (ORs) and their 95% confidence intervals (CIs) were stratified by high-income countries (HICs) versus LMICs using the random-effects model. Twenty-five articles were included in the final analysis encompassing a total study population of 31,949,418 people. There were 17 retrospective cohort studies, 2 prospective cohort studies, 1 case-control study, and 5 pre-post design studies. There were 16 studies from HICs and 9 from LMICs. The median NOS score was 6 with a range of 4 to 9. All studies demonstrated higher odds of helmet usage after implementation of helmet law; however, the results were statistically significantly greater in HICs (OR: 53.5; 95% CI: 28.4; 100.7) than in LMICs (OR: 4.82; 95% CI: 3.58; 6.49), p-value comparing both strata < 0.0001. There were significantly lower odds of motorcycle fatalities after enactment of helmet legislation (OR: 0.71; 95% CI: 0.61; 0.83) with no significant difference by income classification, p-value: 0.27. Odds of TBI were statistically significantly lower in HICs (OR: 0.61, 95% CI 0.54 to 0.69) than in LMICs (0.79, 95% CI 0.72 to 0.86) after enactment of law (p-value: 0.0001). Limitations of this study include variability in the methodologies and data sources in the studies included in the meta-analysis as well as the lack of available literature from the lowest income countries or from the African WHO region, in which helmet laws are least commonly present. CONCLUSIONS: In this study, we observed that mandatory helmet laws had substantial public health benefits in all income contexts, but some outcomes were diminished in LMIC settings where additional measures such as public education and law enforcement might play critical roles.


Asunto(s)
Accidentes de Tránsito/prevención & control , Traumatismos Craneocerebrales/prevención & control , Países en Desarrollo/economía , Salud Global/legislación & jurisprudencia , Dispositivos de Protección de la Cabeza , Renta , Aplicación de la Ley , Motocicletas/legislación & jurisprudencia , Accidentes de Tránsito/legislación & jurisprudencia , Accidentes de Tránsito/mortalidad , Traumatismos Craneocerebrales/etiología , Traumatismos Craneocerebrales/mortalidad , Salud Global/economía , Humanos , Formulación de Políticas , Factores Protectores , Medición de Riesgo , Factores de Riesgo
18.
Best Pract Res Clin Anaesthesiol ; 35(3): 293-306, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34511220

RESUMEN

International hospitals and healthcare facilities are facing catastrophic financial challenges related to the COVID-19 pandemic. The American Hospital Association estimates a financial impact of $202.6 billion in lost revenue for America's hospitals and healthcare systems, or an average of $50.7 billion per month. Furthermore, it could cost low- and middle-income countries ~ US$52 billion (equivalent to US$8.60 per person) each four weeks to provide an effective healthcare response to COVID-19. In the setting of the largest daily COVID-19 new cases in the US, this burden will influence patient care, surgeries, and surgical outcomes. From a global economic standpoint, The World Bank projects that global growth is projected to shrink by almost 8% with poorer countries feeling most of the impact, and the United Nations projects that it will cost the global economy around 2 trillion dollars this year. Overall, a lack of preparedness was a major contributor to the struggles experienced by healthcare facilities around the world. Items such as personal protective equipment (PPE) for healthcare workers, hospital equipment, sanitizing supplies, toilet paper, and water were in short supply. These deficiencies were exposed by COVID-19 and have prompted healthcare organizations around the world to invent new essential plans for pandemic preparedness. In this paper, we will discuss the economic impact of COVID-19 on US and international hospitals, healthcare facilities, surgery, and surgical outcomes. In the future, the US and countries around the world will benefit from preparing a plan of action to use as a guide in the event of a disaster or pandemic.


Asunto(s)
COVID-19/economía , COVID-19/epidemiología , Costo de Enfermedad , Atención a la Salud/economía , Salud Global/economía , COVID-19/terapia , Atención a la Salud/tendencias , Salud Global/tendencias , Personal de Salud/economía , Personal de Salud/tendencias , Humanos , Pandemias , Equipo de Protección Personal/economía , Equipo de Protección Personal/tendencias , Estados Unidos/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...